Single Cell Sequencing Market Size, Share and Trends 2025 to 2034

Single Cell Sequencing Market Size and Forecast 2025 to 2034

The global single cell sequencing market size accounted for USD 2.45 billion in 2024 and is expected to exceed around USD 9.91 billion by 2034, growing at a CAGR of 15.00% from 2025 to 2034. Technological advances in the field of genomics are the key factor driving market growth. Also, the increasing incidence of genetic diseases coupled with the collaboration among academic institutions can fuel market growth soon.

Single Cell Sequencing Market Key Takeaways

• North America dominated the global single cell sequencing market in 2024.
• Asia Pacific is expected to grow at the fastest rate over the studied period.
• By product, the consumable segment dominated the market in 2024.
• By product, the instruments segment is expected to grow at the fastest rate over the forecast period.
• By technology, the PCR segment led the global market in 2024.
• By technology, the sequencing segment is expected to grow at the fastest rate during the projected period.
• By application, the oncology segment dominated the market by holding the largest share in 2024.
• By application, the immunology segment is anticipated to grow at the fastest rate over the forecast period.

Application of Artificial Intelligence (AI) in Genome Sequencing Data Analysis

Artificial Intelligence is extensively used in the single cell sequencing market, especially for the classification and identification of pathogens. AI technology can rapidly process NGS data and detect pathogens in samples in no time, which is important for the quick diagnosis of various diseases. Furthermore, AI algorithms can precisely classify pathogens based on the genomic data available, which is essential for controlling their progress and transmission. 

• In January 2025, Nvidia partnered with Illumina to apply genomics and AI technologies to analyze and interpret multi-omics data in drug discovery, clinical research, and human health, the companies said in a collaboration of technology leaders announced early during the 43rd Annual J.P. Morgan Healthcare Conference.

Market Overview

The single cell sequencing market covers the applications of transcriptomic and genomic techniques to analyze isolated single cells. The access to advanced sequencing platforms like long-read technologies, enabled scientists and researchers to create robust and inexpensive sequence data. This technique enabled the identification and characterization of the cells and offered detailed insights into all types of cells.

Single Cell Sequencing Market Growth Factors

• The increasing funding in the biotechnology sector is expected to boost single cell sequencing market growth soon.
• Companies' growing emphasis on product development can propel market growth shortly.
• The ongoing launch of a cutting-edge SCGS solution will likely contribute to the single cell sequencing market expansion over the forecast period.

Market Scope

Market Dynamics

Drivers

Increasing application in precision medicine

The single cell sequencing market in precision medicine offers data on the genetic basis of disorder at the level of an individual cell. It also helps in developing individualized treatment plans, forecasting the risk associated with any disease, and detecting new therapeutic targets. In addition, it offers important data on the development and performance of immune cells in the field of immunology, thus optimizing the innovations in new immunotherapies.

• In March 2024, Curio Bioscience announced the commercialization of the world's first technology that spatially contextualizes single-cell sequencing data, leveraging a breakthrough invention called Slide-tags developed by the Broad Institute of MIT and Harvard and published in Nature this past December. The first stage of Curio's commercialization of this new product is called Curio Trekker.

Restraint

Uncertain reimbursement policies

The major factors impeding the market growth are the limited reimbursement policies and high investment requirements. The limited availability of bioinformatics solutions, along with the high cost associated with the single-cell genome sequencing process, can constrain the single cell sequencing market. Moreover, the increasing geriatric population and growing incidence of chronic conditions can hamper market growth shortly.

Opportunity

Innovations in sequencing technologies

The ongoing innovations in sequencing technologies have substantially impacted the growth of the single cell sequencing market. The launch of next-generation sequencing (NGS) platforms has allowed scientists to sequence big volumes of RNA and DNA at a rapid pace with less cost. Furthermore, the introduction of cutting-edge single-cell sequencing technologies like droplet-based microfluidics platforms has improved the abilities of single-cell genome sequencing. 

• In February 2024,10x Genomics unveiled the next generation of its single-cell technology architecture that will power new assays of its Chromium platform at the Advances in Genome Biology and Technology (AGBT) General Meeting in Orlando, FL.

Product Insights

The consumable segment dominated the single cell sequencing market in 2024. The dominance of the segment can be attributed to the increasing preference by researchers for consumables in the single-cell analysis process and the growing need for associated consumables. Additionally, this segment is important for DNA/RNA sequencing, supporting DNA-based diagnostics and research, which is fuelled by the growing demand for cancer treatment and personalized medicine.

The instruments segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be credited to the fast evolution and acceptance of innovative instruments specially manufactured to align with the changing landscape of the healthcare sector. Also, the single-cell sequencing solution is created for analysis of gene expression in single cells, enabling researchers to know their functions.

• In October 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, unveiled its MiSeq™ i100 Series of sequencing systems, delivering unparalleled benchtop speed and simplicity to advance next-generation sequencing (NGS) for labs. The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems will empower customers to unlock powerful insights.

Technology Insights

The PCR segment led the global single cell sequencing market in 2024. The dominance of the segment can be linked to the increasing collaborations among the different research institutes coupled with the initiatives taken by key market players. Moreover, It is a very critical technique that enables the fast amplification of a particular segment of DNA. PCR creates billions of copies of a special DNA segment.

• In December 2024, QIAGEN launched two new tools for customizing microbial analysis solutions: a first-of-its-kind Custom dPCR Microbial Assays design tool and QIAseq xHYB Custom Microbial Panels. The dPCR tool enables customized primer and probe design for bacterial, fungal, and viral targets.

The th0065 sequencing segment is expected to grow at the fastest rate during the projected period. The growth of the segment can be driven by ongoing developments in sequencing technologies. This is a statistical technique for detecting putative functional elements in various genomes, such as SNP frequency and GC content. In addition, the major advantage of sequencing is it provides a comprehensive analysis of a person's entire genome.

Application Insights

In 2024, the oncology segment dominated the single cell sequencing market by holding the largest share. The dominance of the segment is due to the increasing prevalence of colorectal, prostate, and breast cancers. Furthermore, the segment is growing because of increasing innovations in cancer research, like immunotherapy, precision medicine, and genetic testing. The surge in several R&D activities can soon influence market growth positively.

• In August 2024, Beckman Coulter Life Sciences, in partnership with Illumina, launched the 'promising new approach' to oncology research, delivering faster results with fewer touchpoints. The Illumina TruSightTM Oncology 500 DNA/RNA assay on the Biomek NGeniuS System from Beckman Coulter Life Sciences provides an innovative automated solution enabling comprehensive genomic profiling of tumor samples according to the companies.

The immunology segment is anticipated to grow at the fastest rate over the forecast period. The growth of the segment can be linked to the developments in single-cell sequencing technologies, including enhanced bioinformatics tools and droplet-based methods, which have made it convenient to process large amounts of individual cells swiftly. The increasing prevalence of autoimmune diseases like multiple sclerosis and rheumatoid arthritis can lead to market expansion further.

Regional Insights

North America dominated the global single cell sequencing market in 2024. The dominance of the segment can be attributed to the increasing prevalence of cancer and chronic diseases and innovative product launches. Also, growing collaboration among key companies, along with the surging biotechnology and pharmaceutical industries, can fuel market growth further. Moreover, in North America, the US led the market owing to the numerous government initiatives and strong research and development facilities.

Asia Pacific is expected to grow at the fastest rate in the single cell sequencing market over the studied period. The growth of the region can be credited to the growing geriatric population which is contributing to the growing incidence of chronic diseases. Furthermore, the significant growth in healthcare infrastructure, facilitated by the economic development in emerging economies like India and Indonesia, can soon boost market growth in the region.

• In August 2023, BioSkryb Genomics entered into a collaboration with Research Instruments to distribute BioSkryb's ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

Single Cell Sequencing Market Companies

• Becton, Dickinson, and Company 
• Danaher Corporation 
• NanoCellect Biomedical 
• Thermo Fisher Scientific, Inc. 
• 10x Genomics 
• Fluxion Biosciences 
• Promega Corporation 
• Luminex Corporation 
• Illumina, Inc. 
• Bio-Rad Laboratories 
• Cytek Biosciences 
• Corning Incorporated 
• Fluidigm Corporation 
• Agilent Technologies, Inc. 

Latest Announcement by Market Players

• In February 2024, Cell Microsystems announced a strategic partnership with OMNI Life Science (OLS), a renowned German cell biology company. This collaboration aims to introduce three revolutionary products - the CERO, CASY, and TIGR - to the United States and Canadian markets, marking a significant step in advancing life science research in North America.  
• In January 2025, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits. The single-flow-cell NovaSeq X Sequencing System offers the same high-quality flow cells and speed as the NovaSeq X Plus Sequencing System.

Recent Developments

• In May 2024, SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company renowned for its leadership in data-driven medicine, announced a collaboration with Microsoft and NVIDIA. This partnership aims to utilize their combined expertise in technology and genomics to develop a streamlined and scalable whole genome sequencing (WGS).
• In February 2023, Thermo Fisher Scientific, Inc. unveiled the TrueMark STI Select Panel, a PCR test intended for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, specifically for research purposes.
• In March 2023, Illumina, Inc. introduced Connected Insights, a cloud-based software designed for tertiary analysis of clinical next-generation sequencing data. This innovative tool aids in genomic profiling for advanced tumors and whole-genome sequencing for rare diseases, among other advanced applications.

Segments Covered in the Report

By Product

• Consumable
• Instruments

By Technology

• Sequencing
• PCR

By Application

• Immunology
• Oncology

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa